19 jun: Offentliggørelse af prospekt og Central Investorinformation for I..
19 jun: Investeringsforeningen Formuepleje – Opdateret prospekt
19-06-2019 13:57:42

Major Shareholder Announcement

Company Announcement

  • Major shareholder announcement for Genmab A/S

Copenhagen, Denmark; June 19, 2019 –

Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 30 of the Danish Capital Markets Act that BlackRock, Inc. has informed us that, as of June 14, 2019, BlackRock, Inc. increased their total ownership (indirectly owned shares and financial instruments) in Genmab A/S to 3,085,723 shares, which amounted to 5.0 % of the share capital and voting rights in Genmab A/S. However, at the same time they informed us that, as of June 17, 2019, BlackRock, Inc. has decreased their total ownership in Genmab A/S to 3,081,714 shares thereby falling below 5% of the share capital and voting rights in Genmab A/S.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products.  Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          

Marisol Peron, Corporate Vice President, Communications & Investor Relations

T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:

Andrew Carlsen, Senior Director, Investor Relations

T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Company Announcement no. 26

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

logo.jpg

Relateret indhold
19 jul - 
Fredagens aktier: Pandora fik stryg på børsen og tynged..
19 jul - 
Aktier/middag: Halter efter Europa trods plusser - især..
19 jul - 
Aktier/åbning: Ørsted dribler eliteindekset i plus
Relateret debat
21 jul - 
Hvis pengene kan anbringes i noget med et afkast %svare..
21 jul - 
Enhver kap udv er altid en udvanding. Alle nøgletal vil..
21 jul - 
Når de 5 % nye aktier betales med Ca dagskursen ser jeg..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
21 jul
GEN
Hmm. Det er med blandede følelser jeg for tid til anden følger med i Genmab trådende. Da Genmab s b..
16
16 jul
GEN
Med markering:   https://ir.genmab.com/news-releases/news-release-details/genmab-announces-net-sales..
7
16 jul
GEN
Evt godkendelse forventes ultimo 2019 og på markedet  Q1 20 SC-behandlingen bliver sandsynligvis væs..
5
16 jul
GEN
Markedsværdi ca. 75 mia for hele butikken svarer vel stort set til den pris som Celgene for ca. 2 år..
5
19 jul
GEN
Mon vi skal igennem de 1234 idag    https://www.euroinvestor.dk/nyheder/2019/07/19/genmab-barclays-s..
4
16 jul
GEN
Nogle analytikere påpeger at trækker man valuta og engangs pillerier ud, så er det som forventet, do..
4
19 jul
GEN
Genmab Announces Submission of Extension of Marketing Authorization to European Medicines Agency for..
3
16 jul
GEN
"en grådig ledelse som man tænker vil gøre alt for at øge kursen"   Den er jeg med på. 
3
16 jul
GEN
Ang. analytiker kommentarer. Jeg er kunde i Nordea og har derfor mulighed for at læse Novrods Genmab..
3
16 jul
GEN
vækst:   1. ste kvartal fra 2018 til 2019:   46 %   2. en kvartal fra 2019 til 2019:   51 %   Vækste..
3

Aktier/tendens: Ørsted tiltænkt helterolle i positiv aktieåbning

19-07-2019 08:09:28
Der er positive nyheder fra både den danske energikoncern Ørsted og biotekselskabet Genmab som oplæg til fredagens danske aktiehandel, hvor markedet før åbningen generelt er bagud i forhold til den stigning de amerikanske aktier præsterede i torsdagens handel.Sammen med stigende futures for både det amerikanske S&P 500-indeks og for det tyske DAX-indeks tidlig fredag morgen peger det mod en positi..

Danske Bank Q2: Kundeflugten fortsætter i udfordret bank

18-07-2019 11:06:22
Kunder siger fortsat farvel til Danske Bank - omend i et langsommere tempo end tidligere. I andet kvartal valgte 4300 Nemkonto-kunder at slukke for den forbindelse til banken, hvor de første seks måneder samlet gav en kundeafgang på 13.600 Nemkonto-kunder svarende til 1 pct. af bankens Nemkonto-kundebase.Det er fortsat bankens hvidvasksag i Estland, der danner ringe i vandet - men også sagen om pr..

Aktier/tendens: Storbanker i fokus efter årle morgen-regnskaber

18-07-2019 08:26:01
Det er storbankerne Nordea og Danske Bank, der tager overskrifterne på det danske aktiemarked torsdag morgen og lægger retningen for børsens C25-indeks, der samtidig vil være presset af internationale kursfald.I USA lukkede Wall Street med fald i størrelsesordenen 0,4-0,7 pct., og i futuresmarkedet er faldene blevet uddybet med yderligere 0,3-0,5 pct.I Asien har investorernes mangel på begejstring..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. juli 2019 03:35:16
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190703.1 - EUROWEB6 - 2019-07-22 03:35:16 - 2019-07-22 03:35:16 - 1 - Website: OKAY